Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

New SHTAC research article on cost effectiveness of multiple myeloma treatment

Published: 4 February 2014

A new research article on the cost effectiveness of first-line treatments for multiple myeloma has been published in the International Journal of Technology Assessment in Health Care.

The International Journal of Technology Assessment in Health Care has just published an article exploring the differences between cost effectiveness models for the first-line treatment of multiple-myeloma. Multiple myeloma is the second most common haematological cancer in the UK but remains an incurable disease. Treatment aims to prolong survival and maintain health related quality of life. This study concerned patients not eligible to withstand intensive treatment. These patients are offered therapies such as bortezomib in combination with melphalan and prednisolone (VMP) and thalidomide in combination with melphalan and prednisolone (MPT) versus melphalan and prednisolone (MP). The article compares the cost effectiveness models produced by the drug manufacturers and by SHTAC for a recent technology appraisal by National Institute of Health and Care Excellence. The study found that the models provide conflicting results, influenced by factors such as the estimates of treatment effectiveness used, and drug costs.   

The full report has been published in Health Technology Assessment, one of the suite of open access journals in the National Institute for Health Research (NIHR) Journals Library series.

For more information on SHTAC's research in cancer please visit our Research page.

Privacy Settings